Refine
Has Fulltext
- yes (24)
Is part of the Bibliography
- yes (24)
Year of publication
Document Type
- Journal article (24)
Language
- English (24)
Keywords
- glioblastoma multiforme (6)
- glioblastoma (5)
- recurrence (5)
- astrocytoma (4)
- mRNA (3)
- protein (3)
- relapse (3)
- therapy (3)
- CNS disorders (2)
- MPS1 (2)
- Tumor Treating Fields (TTFields) (2)
- blood–brain barrier (2)
- brain (2)
- expression (2)
- glioma (2)
- low-grade glioma (2)
- organoids (2)
- temozolomide (2)
- vestibular schwannoma (2)
- 3D ex vivo models (1)
- 3D in vitro model (1)
- ADAM9 (1)
- Astrocytic tumor (1)
- Bevacizumab (1)
- Blood–brain barrier (1)
- CNS diseases (1)
- CX3CL1 (1)
- CXCL13 (1)
- CXCR4 (1)
- Expression (1)
- Glioblastom (1)
- Glioblastoma (1)
- Glioblastoma cell line (1)
- Glioblastoma multiforme (1)
- Glioblastomas (1)
- HERV-K (1)
- Human endogenous retrovirus (1)
- IDH (1)
- In vitro models (1)
- Irradiation (1)
- MGMT (1)
- MGMT promoter methylation (1)
- Merlin (1)
- Metalloproteinasen (1)
- Metastatic breast cancer (1)
- N-Myc down regulated gene 1 (1)
- PCDHGC3 (1)
- PCR analysis (1)
- PET/CT (1)
- Pentixafor (1)
- Short dsRNA oligonucleotides (1)
- Spinal dissemination (1)
- Strahlentherapie (1)
- TTFields (1)
- TTK (1)
- Temozolomide (1)
- Tumor-Treating Fields (TTFields) (1)
- WNT signaling (1)
- aging (1)
- anticancer activity (1)
- astrocytic tumor (1)
- behavior (1)
- blood-brain barrier (1)
- brain cancer (1)
- cancer stem cells (1)
- expression pattern (1)
- glioblastoma cell-lines (1)
- glioblastoma multiforme (GBM) (1)
- growth pattern (1)
- human brain microvascular endothelial cells (HBMVEC) (1)
- human cancer diseases (1)
- human cells (1)
- immunofuorescence double staining (1)
- in vitro model (1)
- integrin (1)
- knock down (1)
- liponeurocytoma (1)
- liquid biopsy (1)
- mRNA expression (1)
- matrix metalloproteinase (1)
- mechanism of action (1)
- medulloblastoma (1)
- metastasis (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- molecular imaging (1)
- molecular signature (1)
- multifocal growth (1)
- neurocytoma (1)
- non-small cell lung cancer (NSCLC) (1)
- organotypic hippocampal slice cultures (OHSC) (1)
- ovarian cancer (1)
- palladium (1)
- pancreatic cancer (1)
- pathogenesis (1)
- platinum (1)
- primary cell culture (1)
- prognostic marker (1)
- protein and mRNA expression (1)
- radiotherapy (1)
- resistance (1)
- senescence (1)
- slice culture (1)
- suppressor (1)
- taxanes (1)
- therapy response (1)
- thiosemicarbazone (1)
- tumor slice cultures (1)
- tumormicroenvironment (1)
Institute
- Neurochirurgische Klinik und Poliklinik (22)
- Pathologisches Institut (13)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (5)
- Frauenklinik und Poliklinik (3)
- Neurologische Klinik und Poliklinik (2)
- Graduate School of Life Sciences (1)
- Institut für Anatomie und Zellbiologie (1)
- Institut für Anorganische Chemie (1)
- Kinderklinik und Poliklinik (1)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (1)
The metastatic suppressor BRMS1 interacts with critical steps of the metastatic cascade in many cancer entities. As gliomas rarely metastasize, BRMS1 has mainly been neglected in glioma research. However, its interaction partners, such as NFκB, VEGF, or MMPs, are old acquaintances in neurooncology. The steps regulated by BRMS1, such as invasion, migration, and apoptosis, are commonly dysregulated in gliomas. Therefore, BRMS1 shows potential as a regulator of glioma behavior. By bioinformatic analysis, in addition to our cohort of 118 specimens, we determined BRMS1 mRNA and protein expression as well as its correlation with the clinical course in astrocytomas IDH mutant, CNS WHO grade 2/3, and glioblastoma IDH wild-type, CNS WHO grade 4. Interestingly, we found BRMS1 protein expression to be significantly decreased in the aforementioned gliomas, while BRMS1 mRNA appeared to be overexpressed throughout. This dysregulation was independent of patients’ characteristics or survival. The protein and mRNA expression differences cannot be finally explained at this stage. However, they suggest a post-transcriptional dysregulation that has been previously described in other cancer entities. Our analyses present the first data on BRMS1 expression in gliomas that can provide a starting point for further investigations.